Evaluating the rising incidence of infant botulism and the heterogeneous distribution of cases in Texas in the wake of the November 2025 outbreak.

BACKGROUND

Infant botulism is a rare, life-threatening neuroparalytic illness. Its rapid progression necessitates early clinical detection and prompt treatment to prevent respiratory failure. Its rising national and regional incidence trends were evaluated and analyzed with a focus on epidemiology within the public health regions (PHR) in Texas and recent outbreaks affecting the state.

METHODS

A retrospective analysis of Centers for Disease Control and Prevention National Botulism Surveillance System (2000-2021) and Texas Department of State Health Services reports (2006-2023) was performed. Incidence rates, incidence rate ratios (IRR), and confidence intervals (CI) were calculated using Poisson-based statistical methods.

RESULTS

The overall incidence of IB in the US has been on the rise from 2000 to 2021 (annual IRR 1.042; 95% CI 1.035-1.048; P < 0.001). Texas showed a similar rise from 2006 to 2023 (annual IRR 1.063; 95% CI 1.028-1.100; P < 0.001). Regional analysis showed a heterogeneous distribution in Texas, with the highest incidence rate in certain regions with significant rural makeup (PHRs 4, 9, and 10) during the years 2006 to 2018.

CONCLUSION

The rising incidence and recent industrial outbreak highlight the need for increased clinical suspicion, particularly in PHRs 4, 9, and 10, as well as stricter regulatory oversight of infant formula supply chains.